Área Oncología

Grupo de Investigación en Neoplasias de Línea Mieloide

Mar Tormo Díaz

 

Grupo de investigación en Neoplasias de Línea Mieloide

Investigador colaborador

Vicente Martín Guillem Primo
Blanca Navarro Cubells
Marisa Calabuig Muñoz
Montserrat Gómez Calafaz
  • Estudios de nuevos factores pronósticos biológicos en leucemia aguda mieloblástica (en colaboración con el grupo cooperativo CETLAM).
  • Guías clínicas de diagnostico, pronóstico y tratamiento de los síndromes mielodisplásicos (en colaboración con el grupo cooperativo GESMD).
  • Estudio de factores que influyen en el riesgo de trombosis en síndromes mieloproliferativos Filadelfia-negativos.
  • Registro Español de Mielofibrosis.
Número total de publicaciones: 88. Factor de Impacto acumulado: 483.96
Long-term results of prednisone treatment for the anemia of myelofibrosis.
Hernández-Boluda JC, Martínez-Trillos A, García-Gutiérrez V, Ferrer-Marín F, Xicoy B, Alvarez-Larrán A, Kerguelen A, Barba P, Gómez M, Herrera JC, Correa JG, Cervantes F
Leukemia & lymphoma.. 2016 Jan. 120-4. FI: 2.891
The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab.
Forero-Castro M, Robledo C, Lumbreras E, Benito R, Hernández-Sánchez JM, Hernández-Sánchez M, García JL, Corchete-Sánchez LA, Tormo M, Barba P, Menárguez J, Ribera J, Grande C, Escoda L, Olivier C, Carrillo E, García de Coca A, Ribera JM, Hernández-Rivas JM
British journal of haematology.. 2016 Feb. 428-38. FI: 4.711
Treatment patterns of adjuvant interferon-?2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study.
Espinosa E, Soriano V, Malvehy J, Berrocal A, Martínez de Prado P, Quindós M, Soria A, Márquez-Rodas I, Palacio I, Cerezuela P, López-Vivanco G, Alonso L, Samaniego E, Ballesteros A, Puértolas T, Díaz-Beveridge R, de la Cruz-Merino L, López Castro R, López López R, Stevinson K, Del Barrio P, Tornamira MV, Guillém V, Martín-Algarra S
Melanoma research.. 2016 Jun. 278-83. FI: 2.282
Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera.
Gómez M, Guillem V, Pereira A, Ferrer-Marín F, Álvarez-Larrán A, Kerguelen A, Estrada N, Martínez-López J, Angona A, Amat P, Navarro B, Besses C, Hernández-Boluda JC
European journal of haematology.. 2016 Mar. 285-90. FI: 2.066
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
Alvarez-Larrán A, Pérez-Encinas M, Ferrer-Marin F, Hernández-Boluda JC, Ramírez MJ, Martínez-López J, Magro E, Cruz Y, Mata MI, Aragües P, Fox ML, Cuevas B, Montesdeoca S, Hernández-Rivas JA, García-Gutiérrez V, Gómez-Casares MT, Steegmann JL, Durán MA, Gómez M, Kerguelen A, Bárez A, García MC, Boqué C, Raya JM, Martinez C, Albors M, Garcia F, Burgaleta C, Besses C
Haematologica.. 2016 Sep 29. . FI: 6.671
Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method.
Besses C, Hernández-Boluda JC, Pérez Encinas M, Raya JM, Hernández-Rivas JM, Jiménez Velasco A, Martínez Lopez J, Vicente V, Burgaleta C, GEMFIN
Annals of hematology.. 2016 Apr. 719-32. FI: 2.634
Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.
Arenillas L, Calvo X, Luño E, Senent L, Alonso E, Ramos F, Ardanaz MT, Pedro C, Tormo M, Marco V, Montoro J, Díez-Campelo M, Brunet S, Arrizabalaga B, Xicoy B, Andreu R, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz GF, Florensa L
Journal of clinical oncology: official journal of the American Society of Clinical Oncology.. 2016 Jul 5. . FI: 20.982
Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.
Ramos F, Robledo C, Izquierdo-García FM, Suárez-Vilela D, Benito R, Fuertes M, Insunza A, Barragán E, Del Rey M, de Morales JM, Tormo M, Salido E, Zamora L, Pedro C, Sánchez-Del-Real J, Díez-Campelo M, Del Cañizo C, Sanz GF, Hernández-Rivas JM, Spanish Group for Myelodysplastic Syndromes (GESMD)
Oncotarget. 2016 Apr 26. . FI: 6.359
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with CALR mutation.
Alvarez-Larrán A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, Ferrer-Marín F, Samah A, Griesshammer M, Kerguelen A, Andreasson B, Burgaleta C, Schwarz J, García-Gutiérrez V, Ayala R, Barba P, Gómez-Casares MT, Paoli C, Drexler B, Zweegman S, McMullin MF, Samuelsson J, Harrison C, Cervantes F, Vannucchi AM, Besses C
Haematologica.. 2016 May 12. . FI: 5.814
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists.
De Stefano V, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Rossi E, Betti S, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola R, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, Carobbio A, Griesshammer M, Sant'Antonio E, Vannucchi AM, Barbui T
Leukemia.. 2016 May 13. . FI: 10.431
Impact of anaemia on health-related quality of life and cardiac remodelling in patients with lower risk myelodysplastic syndromes. Results of GlobQoL study.
Ramos F, Pedro C, Tormo M, de Paz R, Font P, Luño E, Caballero M, Solano F, Almagro M, Xicoy B, Jiménez M
European journal of cancer care.. 2016 Jan 4. . FI: 1.564
Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes.
Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Ardanaz MT, Pedro C, Tormo M, Montoro J, Díez-Campelo M, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz GF, Florensa L
Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc.. 2016 Aug 26. . FI: 5.485
Feasibility of the AML profiler (Skyline™ Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approach.
Nomdedéu JF, Puigdecanet E, Bussaglia E, Hernández JJ, Carricondo M, Estivill C, Martí-Tutusaus JM, Tormo M, Zamora L, Serrano E, Perea G, de Llano MP, García A, Sánchez-Ortega I, Ribera JM, Nonell L, Aventin A, Solé F, Brunet MS, Sierra J
Hematological oncology.. 2016 May 3. . FI: 3.084
Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols.
Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Brunet S, Bergua J, Tormo M, García-Boyero R, Sarrà J, Del Potro E, Grande C, Barba P, Bernal T, Amigo ML, Grau J, Cervera J, Feliu E, PETHEMA Group, Spanish Society of Hematology
Leukemia & lymphoma.. 2016 Apr 27. 42583. FI: 2.891
Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera.
Alvarez-Larrán A, Kerguelen A, Hernández-Boluda JC, Pérez-Encinas M, Ferrer-Marín F, Bárez A, Martínez-López J, Cuevas B, Mata MI, García-Gutiérrez V, Aragües P, Montesdeoca S, Burgaleta C, Caballero G, Hernández-Rivas JA, Durán MA, Gómez-Casares MT, Besses C, Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
British journal of haematology.. 2016 Mar. 786-93. FI: 4.971
Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group.
Ribera JM, García O, Oriol A, Gil C, Montesinos P, Bernal T, González-Campos J, Lavilla E, Ribera J, Brunet S, Martínez MP, Tormo M, Genescà E, Barba P, Sarrà J, Monteserín MC, Soria B, Colorado M, Cladera A, García-Guiñón A, Calbacho M, Serrano A, Ortín X, Pedreño M, Amigo ML, Escoda L, Feliu E, PETHEMA Group, Spanish Society of Hematology
Leukemia research.. 2016 Feb. 44166. FI: 2.351
[JAK2 inhibitors].
Hernández Boluda JC, Gómez M, Pérez A
Medicina clínica.. 2016 Mar 28. . FI: 1.417
Alleviating anemia and thrombocytopenia in myelofibrosis patients.
Cervantes F, Correa JG, Hernandez-Boluda JC
Expert review of hematology.. 2016 May. 489-96. FI: 2.07
[Risk assessment for trombosis and survival in essential thrombocythemia].
Hernández Boluda JC
Medicina clinica. 2015 Mar 15. 257-8. FI: 1.417
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S, COMFORT Investigators
Haematologica.. 2015 Sep. 1139-45. FI: 5.814
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
Sanz MA, Montesinos P, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte MR, Martínez L, Jacomo RH, Gutiérrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Vellenga E, Holowiecka A, González-Huerta AJ, Fernández P, De la Serna J, Brunet S, De Lisa E, González-Campos J, Ribera JM, Krsnik I, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Rego EM, IC-APL and PETHEMA and HOVON Groups
Annals of hematology.. 2015 Aug. 1347-56. FI: 2.634
Association of RBP4 genetic variants with childhood obesity and cardiovascular risk factors.
Codoñer-Franch P, Carrasco-Luna J, Allepuz P, Codoñer-Alejos A, Guillem V
Pediatric diabetes.. 2015 Nov 26. . FI: 2.569
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.
Ramos F, Thépot S, Pleyer L, Maurillo L, Itzykson R, Bargay J, Stauder R, Venditti A, Seegers V, Martínez-Robles V, Burgstaller S, Récher C, Debén G, Gaidano G, Gardin C, Musto P, Greil R, Sánchez-Guijo F, Fenaux P, European ALMA Investigators
Leukemia research. 2015 Mar. 296-306. FI: 2.351
BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia.
Guillem V, Amat P, Collado M, Cervantes F, Alvarez-Larrán A, Martínez J, Tormo E, Eroles P, Solano C, Hernández-Boluda JC
Leukemia research.. 2015 Aug 28. . FI: 2.351
Complex Measurements May Be Required to Establish the Prognostic Impact of Immunophenotypic Markers in AML.
García-Dabrio MC, Hoyos M, Brunet S, Tormo M, Ribera JM, Esteve J, Gallardo D, Duarte RF, de Llano MP, Bargay J, Martí-Tutusaus JM, Heras I, Garcia A, Salamero O, Aventin A, Lecrevisse Q, Orfao A, Sierra J, Nomdedéu JF
American journal of clinical pathology. 2015 Sep. 484-92. FI: 2.514
Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results.
Cervantes F, Isola IM, Alvarez-Larrán A, Hernández-Boluda JC, Correa JG, Pereira A
Annals of hematology.. 2015 Nov. 1791-6. FI: 2.634
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.
Bernal T, Martínez-Camblor P, Sánchez-García J, de Paz R, Luño E, Nomdedeu B, Ardanaz MT, Pedro C, Amigo ML, Xicoy B, del Cañizo C, Tormo M, Bargay J, Valcárcel D, Brunet S, Benlloch L, Sanz G, Spanish Group on Myelodysplastic Syndromes, PETHEMA Foundation, Spanish Society of Hematology
Leukemia.. 2015 Sep. 1875-81. FI: 10.431
Effects of metformin on mitochondrial function of leukocytes from polycystic ovary syndrome patients with insulin resistance.
Victor VM, Rovira-Llopis S, Bañuls C, Diaz-Morales N, Castelló R, Falcón R, Gómez M, Rocha M, Hernández-Mijares A
European journal of endocrinology. 2015 Nov. 683-91. FI: 4.069
Fluorescence in situ hybridization analysis does not increase detection rate for trisomy 8 in chronic myelomonocytic leukemia.
Saumell S, Florensa L, Rodríguez-Rivera M, Pedro C, Hernández-Rivas JM, Lumbreras E, Abáigar M, Collado R, Ivars D, Carbonell F, Marugán I, Tormo M, Botia M, Piñan MÁ, Ancín I, González T, Varela ND, Grau J, Granada I, Ruiz N, Martín ML, Fernández-Guijarro M, Duarte JJ, Calasanz MJ, Larrayoz MJ, Solé F
Leukemia & lymphoma. 2015 Jan. 242-3. FI: 2.891
Metformin modulates human leukocyte/endothelial cell interactions and proinflammatory cytokines in polycystic ovary syndrome patients.
Victor VM, Rovira-Llopis S, Bañuls C, Diaz-Morales N, Lopez-Domenech S, Escribano-López I, Rios-Navarro C, Alvarez A, Gomez M, Rocha M, Hernandez-Mijares A
Atherosclerosis. 2015 Jul 10. 167-173. FI: 3.994
Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score.
Falantes J, Delgado RG, Calderón-Cabrera C, Márquez-Malaver FJ, Valcarcel D, de Miguel D, Bailén A, Bargay J, Bernal T, González-Porras JR, Tormo M, Ramos F, Andreu R, Xicoy B, Nomdedeu B, Brunet S, Sánchez J, Jurado AF, Bonanad S, Pérez-Simón JA, Sanz G, Spanish Group of Myelodysplastic Syndromes (GESMD)
Leukemia research. 2015 Jan. 52-7. FI: 2.351
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia.
Hernández-Boluda JC, Arellano-Rodrigo E, Cervantes F, Alvarez-Larrán A, Gómez M, Barba P, Mata MI, González-Porras JR, Ferrer-Marín F, García-Gutiérrez V, Magro E, Moreno M, Kerguelen A, Pérez-Encinas M, Estrada N, Ayala R, Besses C, Pereira A, Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
Annals of hematology. 2015 Jun. 911-8. FI: 2.634
Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols.
Ribera J, Morgades M, Zamora L, Montesinos P, Gómez-Seguí I, Pratcorona M, Sarrà J, Guàrdia R, Nomdedeu J, Tormo M, Martínez-Lopez J, Hernández-Rivas JM, González-Campos J, Barba P, Escoda L, Genescà E, Solé F, Millá F, Feliu E, Ribera JM, Spanish PETHEMA Group and the Spanish Society of Hematology
Cancer cytopathology.. 2015 Nov 1. 3809-17. FI: 4.889
Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia.
Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G
European journal of haematology.. 2015 Sep 5. . FI: 2.066
Target hematologic values in the management of essential thrombocythemia and polycythemia vera.
Hernández-Boluda JC, Gómez M
European journal of haematology. 2015 Jan. 42678. FI: 2.066
The CHADS2 Score to Predict Stroke Risk in the Absence of Atrial Fibrillation in Hypertensive Patients Aged 65 Years or Older.
Morillas P, Pallarés V, Fácila L, Llisterri JL, Sebastián ME, Gómez M, Castilla E, Camarasa R, Sandin M, García-Honrubia A, FAPRES registry investigators
Revista espanola de cardiologia (English ed.). 2015 Jun. 485-91
The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
Díaz-Beyá M, Brunet S, Nomdedéu J, Cordeiro A, Tormo M, Escoda L, Ribera JM, Arnan M, Heras I, Gallardo D, Bargay J, Queipo de Llano MP, Salamero O, Martí JM, Sampol A, Pedro C, Hoyos M, Pratcorona M, Castellano JJ, Nomdedeu M, Risueño RM, Sierra J, Monzó M, Navarro A, Esteve J
Blood cancer journal. 2015 Oct 2. e352. FI: 3.467
The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
Díaz-Beyá M, Brunet S, Nomdedéu J, Pratcorona M, Cordeiro A, Gallardo D, Escoda L, Tormo M, Heras I, Ribera JM, Duarte R, de Llano MP, Bargay J, Sampol A, Nomdedeu M, Risueño RM, Hoyos M, Sierra J, Monzo M, Navarro A, Esteve J, Cooperative AML group CETLAM
Oncotarget. 2015 Oct 13. 31613-27. FI: 6.359
Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.
Valcárcel D, Sanz G, Ortega M, Nomdedeu B, Luño E, Diez-Campelo M, Ardanaz MT, Pedro C, Montoro J, Collado R, Andreu R, Marco V, Cedena MT, de Paz R, Tormo M, Xicoy B, Ramos F, Bargay J, Gonzalez B, Brunet S, Muñoz JA, Gomez V, Bailén A, Sanchez J, Merchán B, Del Cañizo C, Vallespí T, Grupo Español de Síndromes Mielodisplásicos (GESMD)
The Lancet. Haematology.. 2015 Jun. e260-6
Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.
Rojas SM, Díez-Campelo M, Luño E, Cabrero M, Pedro C, Calabuig M, Nomdedeu B, Cedena T, Arrizabalaga B, García M, Cerveró C, Collado R, Azaceta G, Ardanaz MT, Muñoz JA, Xicoy B, Rodríguez MJ, Bargay J, Morell MJ, Simiele A, Del Cañizo C
Leukemia research. 2014 Mar. 304-9. FI: 2.692
MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia.
Díaz-Beyá M, Brunet S, Nomdedéu J, Tejero R, Díaz T, Pratcorona M, Tormo M, Ribera JM, Escoda L, Duarte R, Gallardo D, Heras I, Queipo de Llano MP, Bargay J, Monzo M, Sierra J, Navarro A, Esteve J
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2014 Apr. 804-12. FI: 9.379
The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
Hernández-Boluda JC, Pereira A, Gómez M, Boqué C, Ferrer-Marín F, Raya JM, García-Gutiérrez V, Kerguelen A, Xicoy B, Barba P, Martínez J, Luño E, Alvarez-Larrán A, Martínez-López J, Arbelo E, Besses C, Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
Haematologica. 2014 Apr. e55-7. FI: 5.868
Treatment of high-risk philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA
Ribera JM, Oriol A, Morgades M, Montesinos P, Sarrà J, González-Campos J, Brunet S, Tormo M, Fernández-Abellán P, Guàrdia R, Bernal MT, Esteve J, Barba P, Moreno MJ, Bermúdez A, Cladera A, Escoda L, García-Boyero R, Del Potro E, Bergua J, Amigo ML, Grande C, Rabuñal MJ, Hernández-Rivas JM, Feliu E
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 May 20. 1595-604. FI: 17.879
Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain.
Gimenez E, Besses C, Boque C, Velez P, Kerguelen A, Cervantes F, Ferrer-Marin F, Perez-Encinas M, Rodriguez M, Gonzalez JD, Calzada R, Hernandez-Boluda JC
Journal of medical economics. 2014 Jun. 435-41
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Alvarez-Larrán A, Martínez-Avilés L, Hernández-Boluda JC, Ferrer-Marín F, Antelo ML, Burgaleta C, Mata MI, Xicoy B, Martínez-Trillos A, Gómez-Casares MT, Durán MA, Marcote B, Ancochea A, Senín A, Angona A, Gómez M, Vicente V, Cervantes F, Bellosillo B, Besses C
Annals of hematology. 2014 Dec. 2037-43. FI: 2.396
Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome.
Martínez-Trillos A, Pinyol M, Navarro A, Aymerich M, Jares P, Juan M, Rozman M, Colomer D, Delgado J, Giné E, González-Díaz M, Hernández-Rivas JM, Colado E, Rayón C, Payer AR, Terol MJ, Navarro B, Quesada V, Puente XS, Rozman C, López-Otín C, Campo E, López-Guillermo A, Villamor N
Blood. 2014 Jun 12. 3790-6. FI: 9.775
Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.
García-Delgado R, de Miguel D, Bailén A, González JR, Bargay J, Falantes JF, Andreu R, Ramos F, Tormo M, Brunet S, Figueredo A, Casaño J, Medina A, Badiella L, Jurado AF, Sanz G
Leukemia research. 2014 Jul. 744-50. FI: 2.692
The commitment and evaluation of the quality management plan by professionals from accredited stem cell transplant centers in Spain.
Jiménez MJ, Ferra C, García O, de Arriba F, Jiménez S, Insunza A, Calabuig M, Mantecon A, Sánchez J, Torres M, Balsalobre P, Linio J, Jiménez A, Feliu E, Ribera JM
Bone marrow transplantation. 2014 Jul. 990-2. FI: 3.466
Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols.
Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, González-Campos J, Fernández-Abellán P, Tormo M, Bethencourt C, Brunet S, Hernández-Rivas JM, Moreno MJ, Sarrà J, Del Potro E, Barba P, Bernal T, Grande C, Grau J, Cervera J, Feliu E, PETHEMA Group, Spanish Society of Hematology
Cancer. 2014 Dec 15. 3958-64. FI: 4.901
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia.
Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernández-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T
Cancer cell. 2014 Sep 8. 428-42. FI: 23.893
Reply to "The association of red blood cell distribution width and morbid obesity" by Aydin et al.
Vayá A, Alis R, Hernandez-Mijares A, Solá E, Cámara R, Rivera L, Romagnoli M, Laiz B
Clinical biochemistry. 2014 Sep. 1350. FI: 2.229
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
Sánchez-García J, Del Cañizo C, Lorenzo I, Nomdedeu B, Luño E, de Paz R, Xicoy B, Valcárcel D, Brunet S, Marco-Betes V, García-Pintos M, Osorio S, Tormo M, Bailén A, Cerveró C, Ramos F, Diez-Campelo M, Such E, Arrizabalaga B, Azaceta G, Bargay J, Arilla MJ, Falantes J, Serrano-López J, Sanz GF, Spanish Group on Myelodysplastic Syndromes (GES MD)
British journal of haematology. 2014 Jul. 189-201. FI: 4.959
Results of allogeneic stem cell transplantation in the Spanish MDS registry: Prognostic factors for low risk patients.
Díez Campelo M, Sánchez-Barba M, de Soria VG, Martino R, Sanz G, Insunza A, Bernal T, Duarte R, Amigo ML, Xicoy B, Tormo M, Iniesta F, Bailén A, Benlloch L, Córdoba I, López-Villar O, Del Cañizo MC, Spanish Registry of MDS
Leukemia research. 2014 Oct. 1199-206. FI: 2.692
JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: Clinical usefulness for predicting myelofibrotic transformation and thrombotic events.
Alvarez-Larrán A, Bellosillo B, Pereira A, Kerguelen A, Carlos Hernández-Boluda J, Martínez-Avilés L, Fernández-Rodríguez C, Gómez M, Lombardía L, Angona A, Ancochea A, Senín A, Longarón R, Navarro B, Collado M, Besses C
American journal of hematology. 2014 May. 517-23. FI: 3.477
Vascular endothelial growth factor A (VEGFA) gene polymorphisms have an impact on survival in a subgroup of indolent patients with chronic lymphocytic leukemia.
Lozano-Santos C, Martinez-Velasquez J, Fernandez-Cuevas B, Polo N, Navarro B, Millan I, Garcia JM, Collado R, Sanchez-Godoy P, Carbonell F, Garcia-Vela JA, Garcia-Marco JA, Gomez-Lozano N
PloS one. 2014. e101063. FI: 3.534
Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome.
Muñiz C, Martín-Martín L, López A, Sánchez-González B, Salar A, Almeida J, Sancho JM, Ribera JM, Heras C, Peñalver FJ, Gómez M, González-Barca E, Alonso N, Navarro B, Olave T, Sala F, Conde E, Márquez JA, Cabezudo E, Cladera A, García-Malo M, Caballero MD, Orfao A, Spanish Group for the Study of Central Nervous System Disease in Non-Hodgkin Lymphoma
Blood. 2014 Mar 20. 1864-9. FI: 9.775
Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma.
Bellas C, García D, Vicente Y, Kilany L, Abraira V, Navarro B, Provencio M, Martín P
PloS one. 2014. e98169. FI: 3.534
Acral localized acquired cutis laxa.
Martí N, Monteagudo C, Revert A, Reig I, Gámez L, Jordá E
International journal of dermatology. 2013 Aug. 983-6. FI: 1.342
Surgical treatment of gastrointestinal stromal tumours. Analysis of our experience.
Martí Obiol R, Garcés Albir M, López Mozos F, Ortega Serrano J
Cirugía española. 2013 Jan. 38-43. FI: 0.871
False positive rate of an arrayCGH platform for single-cell preimplantation genetic screening and subsequent clinical application on day-3.
Mir P, Rodrigo L, Mercader A, Buendía P, Mateu E, Milán-Sánchez M, Peinado V, Pellicer A, Remohí J, Simón C, Rubio C
Journal of assisted reproduction and genetics. 2013 Jan. 143-9. FI: 1.823
Focal DNA copy number changes in neuroblastoma target MYCN regulated genes.
Kumps C, Fieuw A, Mestdagh P, Menten B, Lefever S, Pattyn F, De Brouwer S, Sante T, Schulte JH, Schramm A, Van Roy N, Van Maerken T, Noguera R, Combaret V, Devalck C, Westermann F, Laureys G, Eggert A, Vandesompele J, De Preter K, Speleman F
PloS one. 2013. e52321. FI: 3.73
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.
Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, Rossi D, Cavalli M, Wijermans P, Ria R, Offidani M, Lahuerta JJ, Liberati AM, Mina R, Callea V, Schaafsma M, Cerrato C, Marasca R, Franceschini L, Evangelista A, Teruel AI, van der Holt B, Montefusco V, Ciccone G, Boccadoro M, Miguel JS, Sonneveld P, Palumbo A
Haematologica. 2013 Jun. 980-7. FI: 5.935
Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab).
Ribera JM, García O, Grande C, Esteve J, Oriol A, Bergua J, González-Campos J, Vall-Llovera F, Tormo M, Hernández-Rivas JM, García D, Brunet S, Alonso N, Barba P, Miralles P, Llorente A, Montesinos P, Moreno MJ, Hernández-Rivas JÁ, Bernal T
Cancer. 2013 May 1. 1660-8. FI: 5.201
Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.
Pratcorona M, Brunet S, Nomdedéu J, Ribera JM, Tormo M, Duarte R, Escoda L, Guàrdia R, Queipo de Llano MP, Salamero O, Bargay J, Pedro C, Martí JM, Torrebadell M, Díaz-Beyá M, Camós M, Colomer D, Hoyos M, Sierra J, Esteve J, Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas
Blood. 2013 Apr 4. 2734-8. FI: 9.06
Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study.
Alvarez-Larrán A, Pereira A, Arellano-Rodrigo E, Hernández-Boluda JC, Cervantes F, Besses C
British journal of haematology. 2013 Jun. 865-71. FI: 4.942
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma.
Sarasquete ME, Martínez-López J, Chillón MC, Alcoceba M, Corchete LA, Paiva B, Puig N, Sebastián E, Jiménez C, Mateos MV, Oriol A, Rosiñol L, Palomera L, Teruel AI, González Y, Lahuerta JJ, Bladé J, Gutiérrez NC, Fernández-Redondo E, González M, San Miguel JF, García-Sanz R
British journal of haematology. 2013 Oct. 223-34. FI: 4.942
Comments on the ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation.
Coordinadores:, Worner F, Cequier A, Grupo de Trabajo de la Sociedad Española de Cardiología para la guía de práctica clínica sobre el síndrome coronario agudo con elevación del segmento ST:, Bardají A, Bodí V, Bover R, Martínez-Sellés M, Sabaté M, Sionis A, Vázquez de Prada JA, Grupo de Revisores Expertos para la guía de síndrome coronario agudo con elevación del segmento ST:, Arós F, Arribas F, Barrabés J, Díaz de Castro O, Heras M, López Palop R, López-Sendón JL, Manito N, de Pablo MC, Ripoll T, San Román A, de la Torre JM, Comité de Guías de Práctica Clínica de la Sociedad Española de Cardiología:, Fernandez-Ortiz A, Alonso Gómez AM, Anguita M, Cequier A, Comín J, Diaz-Buschmann I, Fernández Lozano I, Gómez de Diego JJ, Pan M, Worner F
Revista española de cardiología. 2013 Jan. 41948. FI: 3.204
Nodular lesion on a woman's earlobe.
López V, Giner F
Actas dermo-sifiliográficas. 2013 Jun. 437-8
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis.
Pajares B, Pollán M, Martín M, Mackey JR, Lluch A, Gavila J, Vogel C, Ruiz-Borrego M, Calvo L, Pienkowski T, Rodríguez-Lescure A, Seguí MA, Tredan O, Antón A, Ramos M, Cámara MD, Rodríguez-Martín C, Carrasco E, Alba E
Breast cancer research : BCR. 2013 Nov 6. R105
Images in clinical medicine. Myeloid sarcoma.
Montoro J, Tormo M
The New England journal of medicine. 2013 Dec 12. 2332. FI: 51.658
Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.
Hoyos M, Nomdedeu JF, Esteve J, Duarte R, Ribera JM, Llorente A, Escoda L, Bueno J, Tormo M, Gallardo D, de Llano MP, Martí JM, Aventín A, Mangues R, Brunet S, Sierra J
European journal of haematology. 2013 Sep. 209-18. FI: 2.548
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H, PACE Investigators
The New England journal of medicine. 2013 Nov 7. 1783-96. FI: 51.658
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
Abrisqueta P, Villamor N, Terol MJ, González-Barca E, González M, Ferrà C, Abella E, Delgado J, García-Marco JA, González Y, Carbonell F, Ferrer S, Monzó E, Jarque I, Muntañola A, Constants M, Escoda L, Calvo X, Bobillo S, Montoro JB, Montserrat E, Bosch F
Blood. 2013 Dec 5. 3951-9. FI: 9.06
[Complications after lung transplantation in chronic obstructive pulmonary disease].
Cerón Navarro J, de Aguiar Quevedo K, Mancheño Franch N, Peñalver Cuesta JC, Vera Sempere FJ, Padilla Alarcón J
Medicina clínica. 2013 May 4. 385-9. FI: 1.399
A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera.
Hernández-Boluda JC, Pereira A, Cervantes F, Alvarez-Larrán A, Collado M, Such E, Arilla MJ, Boqué C, Xicoy B, Maffioli M, Bellosillo B, Marugán I, Amat P, Besses C, Guillem V
Blood. 2012 May 31. 5221-8. FI: 9.06
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera.
Alvarez-Larrán A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernández-Boluda JC, Ferrer-Marín F, Angona A, Gómez M, Muiña B, Guillén H, Teruel A, Bellosillo B, Burgaleta C, Vicente V, Besses C
Blood. 2012 Feb 9. 1363-9. FI: 9.06
Absence of mutations in the activation loop and juxtamembrane domains of VEGFR-1 and VEGFR-2 gene in chronic myelomonocytic leukemia (CMML).
Such E, Cervera J, Ibáñez M, Gómez-Seguí I, Luna I, López-Pavía M, Mallo M, Collado R, Vicente A, Hernández-Boluda JC, Luño E, Andreu R, Sanz GF, Sanz MA
Leukemia research. 2012 Mar. e50-1. FI: 2.764
A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia.
Valcárcel D, Montesinos P, Sánchez-Ortega I, Brunet S, Esteve J, Martínez-Cuadrón D, Ribera JM, Tormo M, Bueno J, Duarte R, Llorente A, Torres JP, Guardia R, Sanz MA, Sierra AJ, on behalf of the CETLAM Group
Cancer. 2012 Jan 15. 410-417. FI: 5.201
Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome.
Cordoba I, González-Porras JR, Nomdedeu B, Luño E, de Paz R, Such E, Tormo M, Vallespi T, Collado R, Xicoy B, Andreu R, Muñoz JA, Solé F, Cervera J, Del Cañizo C, On behalf of the Spanish Myelodysplastic Syndrome Registry
Cancer. 2012 Jan 1. 127-133. FI: 5.201
Donor CTLA-4 Genotype Influences Clinical Outcome after T Cell-Depleted Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Identical Sibling Donors.
Bosch-Vizcaya A, Pérez-García A, Brunet S, Solano C, Buño I, Guillem V, Martínez-Laperche C, Sanz G, Barrenetxea C, Martínez C, Tuset E, Lloveras N, Coll R, Guardia R, González Y, Roncero JM, Bustins A, Gardella S, Fernández C, Buch J, Gallardo D, GvHD/Immunotherapy committee of the Spanish Group for Hematopoietic Transplant (GETH)
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2012 Jan. 100-5. FI: 3.94
Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia.
Guillem V, Amat P, Cervantes F, Alvarez-Larrán A, Cervera J, Maffioli M, Bellosillo B, Collado M, Marugán I, Martínez-Ruiz F, Hernández-Boluda JC
Leukemia research. 2012 Feb. 174-81. FI: 2.764
Functional profile of cytomegalovirus (CMV)-specific CD8(+) T cells and kinetics of NKG2C(+) NK Cells associated with the resolution of CMV DNAemia in allogeneic stem cell transplant recipients.
Muñoz-Cobo B, Solano C, Benet I, Costa E, Remigia MJ, de la Cámara R, Nieto J, López J, Amat P, Garcia-Noblejas A, Bravo D, Clari MÁ, Navarro D
Journal of medical virology. 2012 Feb. 259-67. FI: 2.373
Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell transplant recipients.
Clari MÁ, Muñoz-Cobo B, Solano C, Benet I, Costa E, Remigia MJ, Bravo D, Amat P, Navarro D
Clinical and vaccine immunology : CVI. 2012 May. 791-6. FI: 2.598
Polymyositis after donor lymphocyte infusion.
Montoro J, Hernández-Boluda JC, Arbona C, Solano C
International journal of hematology. 2012 Sep. 386-9. FI: 1.681
Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols.
Ribera JM, García O, Fernández-Abellán P, Lavilla E, Bernal MT, González-Campos J, Brunet S, Monteserín MC, Montesinos P, Sarrá J, Calbacho M, Alvarez-Larrán A, Tormo M, Oriol A
British journal of haematology. 2012 Nov. 485-8. FI: 4.942
Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival.
Santamaría C, Ramos F, Puig N, Barragán E, de Paz R, Pedro C, Insunza A, Tormo M, Del Cañizo C, Diez-Campelo M, Xicoy B, Salido E, Sánchez del Real J, Hernández M, Chillón C, Sanz GF, García-Sanz R, San Miguel JF, González M
Annals of hematology. 2012 Dec. 1887-95. FI: 2.866
Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen.
Sanz J, Boluda JC, Martín C, González M, Ferrá C, Serrano D, de Heredia CD, Barrenetxea C, Martinez AM, Solano C, Sanz MA, Sanz GF
Bone marrow transplantation. 2012 Oct. 1287-93. FI: 3.541
Liposomal cytarabine in central nervous system disease of haematological malignancies: more effective but more toxic?
Tormo Díaz M
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2012 Apr. 241-2. FI: 1.276

Papel del complejo RUNX1/CBF-beta/p300/HIPK2 en la progresión leucémica de las neoplasias

Referencia:
SIN EXPEDIENTE INTRAMURAL INCLIVA IV
Investigador principal:
JUAN CARLOS HERNANDEZ BOLUDA
Entidad financiadora:
Fundación Investigación Hospital Clínico Universitario de Valencia
Duración:
01/01/2014 - 31/12/2014
Presupuesto total:
€6.146